Significance of P-cadherin overexpression and methylation status in gastrointestinal cancer.

• Project/Area Number: 24791384
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: General surgery
• Research Institution: Kumamoto University
• Principal Investigator: IMAI katsunori 熊本大学, 医学部附属病院, 非常勤診療医師 (60555746)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: P-cadherin / CDH3 / 肝内胆管癌 / 膵癌 / 脱メチル化

Outline of Final Research Achievements

Clinicopathological and prognostic significance of P-cadherin expression in 59 intrahepatic cholangiocarcinoma (ICC) and 73 pancreatic cancer patients were examined by immunohistochemistry. Multivariate analyses revealed that P-cadherin expression was the independent prognostic factor for disease-free survival in both cancers.Down-regulation of P-cadherin by siRNA suppressed the migration and invasion of both ICC and pancreatic cancer cells,and overexpression of P-cadherin induced the opposite effects in these cancer cells.Methylation-specific PCR analysis revealed that P-cadherin expression was found to be related to its promoter methylation status in both cancer cell lines and tissues.P-cadherin overexpression may serve as a useful biomarker of invasive phenotype and poor prognosis in patients with ICC and pancreatic cancer.The expression of P-cadherin is found to be regulated by its promoter methylation.

Research Products

• [Journal Article] The modified Glasgow Prognostic Score (mGPS) is a good predictor of indication for palliative bypass surgery in patients with unresectable pancreatic and biliary cancers (2014)
  • Author(s): Ikuta Y, Takamori H, Sakamoto Y, Hashimoto D, Chikamoto A, Kuroki H, Sakata K, Sakamoto K, Hayashi H, Imai K, Nitta H, Hirota M, Kanemitsu K, Beppu T, Baba H
  • Journal Title: Int J Clin Oncol Volume: 19(4) Issue: 4 Pages: 629-33
  • DOI: 10.1007/s10147-013-0613-y
  • Peer Reviewed
• [Journal Article] Salvage treatment for local recurrence of hepatocellular carcinoma after local ablation therapy (2014)
  • Author(s): Imai K, Beppu T, Chikamoto A, Mima K, Okabe H, Hayashi H, Nitta H, Ishiko T, Baba H
  • Journal Title: Hepatol Res Volume: 44(14) Issue: 14
  • DOI: 10.1111/hepr.12313
  • Peer Reviewed
• [Journal Article] Clinicopathological and prognostic significance of preoperative serum zinc status in patients with hepatocellular carcinoma after initial hepatectomy (2014)
  • Author(s): Imai K, Beppu T, Yamao T, Okabe H, Hayashi H, Nitta H, Hashimoto D, Mima K, Nakagawa S, Sakamoto K, Chikamoto A, Ishiko T, Baba H
  • Journal Title: Ann Surg Oncol Volume: 21(12) Issue: 12 Pages: 3817-26
  • DOI: 10.1245/s10434-014-3786-3
  • Peer Reviewed
• [Journal Article] study KSGoCCa: Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome (2014)
  • Author(s): Imai K, Emi Y, Iyama KI, Beppu T, Ogata Y, Kakeji Y, Samura H, Oki E, Akagi Y, Maehara Y, Baba H
  • Journal Title: Eur J Surg Oncol Volume: 40(5) Issue: 5 Pages: 559-66
  • DOI: 10.1016/j.ejso.2013.12.009
  • Peer Reviewed
• [Presentation] 肝内胆肝癌におけるP-cadherinの発現と予後との関連 (2013)
  • Author(s): 坂本慶太、今井 克憲、中川 茂樹、岡部 弘尚、新田 英利、林 洋光、近本 亮、石河 隆敏、別府 透、馬場 秀夫
  • Organizer: 第68回日本消化器外科学会
  • Place of Presentation: 宮崎･シーガイヤコンベンションセンター